Zosano Pharma Corp Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2018-11-14: Form 8-K; Period of report 2018-11-14; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2018-10-16: Form 8-K; Period of report 2018-09-25; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2018-10-03: Form 8-K; Period of report 2018-09-27; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2018-09-26: Form 8-K; Period of report 2018-09-25; Description 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2018-11-14 | 8-K | 2018-11-14 | 2.02 Results of Operations and Financial Condition | 2.02 On November 14, 2018, we issued a press released titled “Zosano Pharma Reports Third Quarter 2018 Financial Results and Operational Update.” The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. | d616451d8k.htm |
| 2018-10-16 | 8-K | 2018-09-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On October 16, 2018, Zosano Pharma Corporation (the “Company”) announced that the Company entered into an employment agreement (the “Agreement”) dated September 25, 2018 with Greg Kitchener, age 47, in connection with the commencement of his employment with the Company as Chief Financial Officer (including as the Company’s Principal Financial Officer and Principal Accounting Officer), effective as of October 15, 2018 (the “Start Date”). | d637155d8k.htm |
| 2018-10-03 | 8-K | 2018-09-27 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d629515d8k.htm |
| 2018-09-26 | 8-K | 2018-09-25 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 1.02 On September 25, 2018, the Company terminated the Loan and Security Agreement (the “Loan and Security Agreement”) dated as of June 3, 2014, between the Company and Hercules Technology Growth Capital, Inc. in connection with the entering into of the Lease Agreement. 2.03 The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. 3.02 The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. | d592276d8k.htm |
| 2018-09-24 | 8-K | 2018-09-18 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 18, 2018, Zosano Pharma Corporation (the “Company”) entered into amended and restated employment agreements (the “Agreements”) with Donald Kellerman, Pharm.D., who will continue to serve as Vice President of Clinical Development & Medical Affairs of the Company and Hayley Lewis, who will continue to serve as Senior Vice President of Operations of the Company. | d628688d8k.htm |
| 2018-08-09 | 8-K | 2018-08-09 | 2.02 Results of Operations and Financial Condition | 2.02 On August 9, 2018, we issued a press released titled “Zosano Pharma Reports Second Quarter 2018 Financial Results and Operational Update.” The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. | d573212d8k.htm |
| 2018-08-06 | 8-K | 2018-05-23 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d372864d8k.htm |
| 2018-06-12 | 8-K | 2018-06-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 7, 2018, we entered into a new Employment Letter Agreement (the “Employment Agreement”) with our President and Chief Executive Officer, John Walker. | d410945d8k.htm |
| 2018-06-05 | 8-K | 2018-05-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 At our 2018 annual meeting of stockholders, held on May 31, 2018, our stockholders approved two proposed amendments to our Amended and Restated 2014 Equity and Incentive Plan, as amended (the “2014 Plan”). 5.07 On May 31, 2018, we held our annual meeting of stockholders. | d445889d8k.htm |
| 2018-05-22 | 8-K | 2018-05-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 17, 2018, our Board of Directors elected Steven A. Elms to our Board of Directors to serve as an independent Class II director. | d558319d8k.htm |
| 2018-05-15 | 8-K | 2018-05-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 In connection with Ms. Erbez’s resignation as the Company’s Chief Business Officer and Chief Financial Officer effective on May 15, 2018, the Company entered into a Separation Agreement with Ms. Erbez on May 10, 2018 (the “Separation Agreement”). | d589134d8k.htm |
| 2018-05-15 | 8-K | 2018-05-15 | 2.02 Results of Operations and Financial Condition | 2.02 On May 15, 2018, we issued a press released titled “Zosano Pharma Reports First Quarter 2018 Financial Results and Operational Update.” The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. | d580848d8k.htm |
| 2018-04-20 | 8-K | 2018-04-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 16, 2018, the Compensation Committee and the Board of Directors of Zosano Pharma Corporation (the “Company”) approved bonus payments to each of the Company’s named executive officers in respect of fiscal 2017. | d496326d8k.htm |
| 2018-04-03 | 8-K | 2018-03-28 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d563355d8k.htm |
| 2018-03-12 | 8-K | 2018-03-12 | 2.02 Results of Operations and Financial Condition | 2.02 On March 12, 2018, we issued a press released titled “Zosano Pharma Reports Fourth Quarter and Fiscal 2017 Financial Results and Operational Update.” The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. | d463579d8k.htm |
| 2018-02-12 | 8-K | 2018-02-09 | 8.01 Other Events | 8.01 On February 9, 2018, Zosano Pharma Corporation received a letter from the Director of Nasdaq Listing Qualifications notifying the Company that it has regained compliance with the requirement of the Nasdaq Stock Market to maintain a minimum bid price of $1.00 per share. | d478604d8k.htm |
| 2018-01-25 | 8-K | 2018-01-24 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 5.03 On January 23, 2018, Zosano Pharma Corporation (“we” or the “Company”) held a special meeting of stockholders. 5.07 On January 23, 2018, we held a special meeting of stockholders. 8.01 On January 25, 2018, the Company issued a press release announcing the Reverse Stock Split as described in Item 5.03. | d527393d8k.htm |